Caplacizumab is a medicine that has been developed to treat acquired thrombotic thrombocytopenic purpura (TTP). TTP causes serious symptoms. such as thrombocytopenia, a condition in which a patient doesn’t have enough platelets. A recent Phase I study observed both Caucasian and Japanese participants, and found that the treatment did not show adverse effects in either group.
Read the original article on Globe Newswire here.